No permanent head at EMA for at least six months, interim appointment close?
This article was originally published in Clinica
The management board of the European Medicines Agency is preparing to officially discuss the matter of who might lead the agency on a temporary basis after its current executive director Thomas Lönngren leaves at the end of the year. An interim appointment could be made in early October.
You may also be interested in...
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
If Zolgensma gets the thumbs up from the EMA this week, it will likely get formal EU approval within a couple of months.
BMS should find out mid-2020 whether its new MS drug will be approved in the EU.